🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What is the role of Dato-Dxd in EGFR+ NSCLC? JTO & JTO CRR - pooled analysis TropionLung01+05 - 117pts (med. 3 lines) - ORR 43%, mPFS 5.8m, mOS 15.6m - 60% stomatitis, g3+ 9% Reasonable option, though data not in the era of MARIPOSA+/-2 OncoAlert #LCSM jto.org/article/S1556-…

Pooled data on Dato-DXd in EGFR+ NSCLC from TROPION-Lung05 + 01 👥 117 pts, median 3 prior lines, 82% prior osimertinib ▫️ORR: 43% ▫️DOR: 7 mo ▫️PFS: 5.8 mo ⚠️ Mucositis/stomatitis: 69% ⚠️ Ocular events: 32% ⚠️ ILD/pneumonitis: 4% Jarushka Naidoo LungCancerRx 🫁💊

🧬 A rare & inherited cancer, finally getting attention. 📌 18 June 25 NEJM presents: Bevacizumab + Erlotinib in HLRCC-related pRCC 🔹 ORR: 72% 🔹 Median PFS: 21.1 mo 🔹 Median OS: 44.6 mo 🔗 nejm.org/doi/full/10.10… A breakthrough in an ultra-rare, treatment-resistant

How we translate a genomic classification into treatment! #ICML2025 #18ICML

David Scott’s BC Cancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML Ash Alizadeh, MD/PhD 🇺🇸

CONGRESS | #18ICML | PRESENTATION Michael Wang Michael Wang, MD MD Anderson Cancer Center discusses results from the SYMPATICO study of first-line ibrutinib plus venetoclax in patients with #MantleCellLymphoma who are ≥65 years or have TP53 mutations; concluding that this combination may be

Update on maintenance therapy in Ovarian ca from ISMPO ESMO - Eur. Oncology pan asian adapted guidelines How to choose bw Ola/Nira/Ruca ? Always wondered how PARPis work in HRD- tumors -If anyone can share literature - I'll be glad! Dr Amol Akhade Goutham Sunny Praveen Kumar Marimuthu Ashish Singh

Selecting CAR-T vs BsAbs in r/r follicular #lymphoma 🧐 Meet the professor Gloria Iacoboni reviewing T-cell redirecting therapies in DLBCL and FL! 👏 #ICML2025 #18ICML International Conference on Malignant Lymphoma GELTAMO

CONGRESS | #18ICML | PRESENTATION David Belada, University Hospital and Faculty of Medicine, Hradec Králové, presents results from the epcoritamab monotherapy arm (N = 45) of the phase II EPCORE DLBCL-3 trial assessing the efficacy and safety of epcoritamab or epcoritamab +

#18ICML LBA: DLBclass stratification of POLARIX - Cluster 5 DLBCL had superior PFS with pola-R-CHP vs R-CHOP (including in MV model) - C5: ABC-type, +BCL2, CD79Bmut, MYD88mut, extranodal #lymsm

Preliminary SUNMO trial data (Dr. WETIN): pola + mosunetuzumab vs R-GEMOX in R/R DLBCL (no ASCT candidates) - ORR: 70.3% vs 40% - CR: 51.4% vs 24.3% - PFS: 11.5 vs 3.8 months - Low CRS, acceptable safety 🥊 Another KO for GEMOX #18ICML #ICML2025

CONGRESS | #18ICML | PRESENTATION Christopher Fox Chris Fox Uni of Nottingham #WeAreUoN presents results from Cohort 1 of the phase II PRiZM+ study assessing the safety and efficacy of the zanubrutinib monotherapy in patients with R/R PCNSL (N = 20). The ORR at 8 weeks was 50%, with a

🧪 What’s next in 1L maintenance for OC? 📍 #ESMOGynae 2025 💥 ADCs moving earlier! ▪️ BEV +/- T-DXd (HER2+) ▪️ BEV +/- FRα ADC ▪️ BEV +/- TROP2 ADC 🧬 Vaccines (TEDOPI), BiTEs, ICI combos in trials 🔬 WEE1/CDK2i for CCNE1-high PROC: ORR 30–35% 🤔 Duration? Biomarker-driven

Datopotamab deruxtecan (DatoDXd - Trop2 ADC) now FDA Oncology approved off #TROPIONLung01 & 05 for previously treated mEGFR NSCLC - ORR of 42.7%, mDoR 7.0 mos - mPFS: 5.8 mos and mOS 15.6 mos - AEs: Nausea, stomatitis, and ILD #lcsm #OncTwitter U.S. FDA

🚨Blastic Plasmacytoid Dendritic Cell Neoplasm #BPDCN 🧪Rare, aggressive malignancy 🧴Often presents with skin lesions 🧠CNS involvement common → needs IT chemo 💉Preferred induction: ALL-type intensive chemo 🧬 HMA+VEN or CHOP for less fit patients 🧾 CR achieved? → Allo-HSCT

Pooled analysis of EGFR-mutant NSCLC from TROPION-Lung05 and TROPION-Lung01 was presented at #ESMOASIA24:

Some guidance on side effect management for DatoDXd (based off review article from #DrHeist Aditya Bardia, MD et al. as this is also approved for HR+ breast cancer)! Watch out for ILD, Mucositis, IRR, and Occular toxicities. pubmed.ncbi.nlm.nih.gov/38502995/ #OncTwitter

New video on rhabdomyosarcoma is live! Here is a quick review of staging & risk stratification for RMS. youtu.be/r2JqnisHV34?si…

Linvoseltamab (BCMA-CD3 Tcell bispecific) is now U.S. FDA approved based off LINKER-MM1 study in R/R Multiple Myeloma (at least 4 prior lines of Rx): - ORR was 70% - DoR: 89% at 9mos and 72% at 12 mos - AEs: CRS, ICANS (mainly low grade), Infections #HemeTwitter #mmsm